Physician profile
Rina Meyer
NPI 1205095031
$546.20
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $69.58 · 2021: $132 · 2023: $14.83 · 2024: $65.72 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162 · Consulting Fee: $29.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.28 |
| Consulting Fee | $29.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $123.37 | 2021-2024 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Shire North American Group INC | $110.00 | 2019 | |
| Itf Therapeutics LLC | $83.40 | 2025 | |
| Silvergate Pharmaceuticals, INC. | $41.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.16 | 2020-2023 | |
| Pfizer INC. | $28.26 | 2025 | |
| Genzyme Corporation | $25.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.35 | 2020 | |
| Biogen, INC. | $19.20 | 2024 | Skyclarys |
| Adaptive Biotechnologies Corporation | $16.59 | 2024 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $15.50 | 2020 | |
| Incyte Corporation | $15.40 | 2020 | |
| Sobi, INC | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.